PTAB proceedings are a vital tool in the biologics space, despite low usage rates
While generic enthusiasm for IPRs has waned, administrative challenges are of growing importance to biosimilar producers
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.